Latest & greatest articles for Tocolytic

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Tocolytic or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Tocolytic and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Tocolytic

1. Misoprostol vaginal delivery system (Mysodelle): reports of excessive uterine contractions (tachysystole) unresponsive to tocolytic treatment

Misoprostol vaginal delivery system (Mysodelle): reports of excessive uterine contractions (tachysystole) unresponsive to tocolytic treatment Misoprostol vaginal delivery system (Mysodelle): reports of excessive uterine contractions (tachysystole) unresponsive to tocolytic treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Search Misoprostol vaginal delivery system (Mysodelle): reports of excessive uterine contractions (tachysystole) unresponsive to tocolytic treatment Monitor (...) patients closely and remove the vaginal delivery system immediately in cases of excessive or prolonged uterine contractions, at the onset of labour, or if there is clinical concern for mother or baby. Published 6 February 2018 From: Therapeutic area: Contents Advice for healthcare professionals: Mysodelle can cause uterine tachysystole that may not respond to tocolytic treatment monitor patients closely and remove the vaginal delivery system immediately if any of the following apply: tachysystole: more

2018 MHRA Drug Safety Update

3. Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. (PubMed)

Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. Despite the global burden of morbidity and mortality associated with preterm birth, little evidence is available for use of antenatal corticosteroids and tocolytic drugs in preterm births in low-income and middle-income countries. We analysed data from the WHO Multicountry Survey on Maternal and Newborn Health (WHOMCS) to assess (...) antenatal corticosteroids are known to be most beneficial. We also calculated use in women at 22-25 weeks' and 34-36 weeks' gestation. We assessed tocolytic drug use, with and without antenatal corticosteroids, in spontaneous, uncomplicated preterm deliveries at 26-34 weeks' gestation.Of 303,842 recorded deliveries after 22 weeks' gestation, 17,705 (6%) were preterm. 3900 (52%) of 7547 women who gave birth at 26-34 weeks' gestation, 94 (19%) of 497 women who gave birth at 22-25 weeks' gestation

2014 Lancet

4. Combination of tocolytic agents for inhibiting preterm labour. (PubMed)

Combination of tocolytic agents for inhibiting preterm labour. Preterm birth represents the single largest cause of mortality and morbidity for newborns and a major cause of morbidity for pregnant women. Tocolytic agents include a wide range of drugs that can inhibit labour to prolong pregnancy. This may gain time to allow the fetus to mature further before being born, permit antenatal corticosteroid administration for lung maturation, and allow time for intra-uterine transfer to a hospital (...) with neonatal intensive care facilities. However, some tocolytic drugs are associated with severe side effects. Combinations of tocolytic drugs may be more effective over single tocolytic agents or no intervention, without adversely affecting the mother or neonate.To assess the effects on maternal, fetal and neonatal outcomes of any combination of tocolytic drugs for the treatment of preterm labour when compared with any other treatment, no treatment or placebo.We searched the Cochrane Pregnancy

2014 Cochrane

5. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis

Tocolytic therapy for preterm delivery: systematic review and network meta-analysis Tocolytic therapy for preterm delivery: systematic review and network meta-analysis Tocolytic therapy for preterm delivery: systematic review and network meta-analysis Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ CRD summary This review concluded that prostaglandin inhibitors and calcium channel blockers had the highest probability of delaying delivery and improving neonatal and maternal outcomes (...) . This was a generally well-conducted review and the conclusions are likely to be reliable based on the information available. Authors' objectives To determine the most effective tocolytic agent at delaying delivery in women at risk of preterm delivery. Searching MEDLINE, EMBASE, CINAHL and Cochrane Central Register of Controlled Trials (CENTRAL) were searched without language restrictions to 2012; search terms were reported. Bibliographies of Cochrane reviews were searched for additional studies. Abstracts

2012 DARE.

6. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. (PubMed)

Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. To determine the most effective tocolytic agent at delaying delivery.Systematic review and network meta-analysis.Cochrane Central Register of Controlled Trials, Medline, Medline In-Process, Embase, and CINAHL up to 17 February 2012.Randomised controlled trials of tocolytic therapy in women at risk of preterm delivery.At least two reviewers extracted data on study design, characteristics, number of participants (...) , and outcomes reported (neonatal and maternal). A network meta-analysis was done using a random effects model with drug class effect. Two sensitivity analyses were carried out for the primary outcome; restricted to studies at low risk of bias and restricted to studies excluding women at high risk of preterm delivery (those with multiple gestation and ruptured membranes).Of the 3263 titles initially identified, 95 randomized controlled trials of tocolytic therapy were reviewed. Compared with placebo

Full Text available with Trip Pro

2012 BMJ

7. Tocolytic Drugs Preterm Labour

Tocolytic Drugs Preterm Labour Preterm Labour, Tocolytic Drugs (Green-top Guideline No. 1B) Search Search Toggle navigation Preterm Labour, Tocolytic Drugs (Green-top Guideline No. 1B) Back to guidelines homepage Preterm Labour, Tocolytic Drugs (Green-top Guideline No. 1B) Published: 22/02/2011 This guideline has been archived. Please see the . share this Royal College of Obstetricians and Gynaecologists © 2019 Registered charity no. 213280 27 Sussex Place Regent's Park London NW1 4RG UK Tel

2011 Royal College of Obstetricians and Gynaecologists

8. Tocolytic therapy: a meta-analysis and decision analysis (PubMed)

Tocolytic therapy: a meta-analysis and decision analysis To determine the optimal first-line tocolytic agent for treatment of premature labor.We performed a quantitative analysis of randomized controlled trials of tocolysis, extracting data on maternal and neonatal outcomes, and pooling rates for each outcome across trials by treatment. Outcomes were delay of delivery for 48 hours, 7 days, and until 37 weeks; adverse effects causing discontinuation of therapy; absence of respiratory distress (...) syndrome; and neonatal survival. We used weighted proportions from a random-effects meta-analysis in a decision model to determine the optimal first-line tocolytic therapy. Sensitivity analysis was performed using the standard errors of the weighted proportions.Fifty-eight studies satisfied the inclusion criteria. A random-effects meta-analysis showed that all tocolytic agents were superior to placebo or control groups at delaying delivery both for at least 48 hours (53% for placebo compared with 75-93

Full Text available with Trip Pro

2009 EvidenceUpdates

9. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. (PubMed)

Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. To evaluate the incidence of serious maternal complications after the use of various tocolytic drugs for the treatment of preterm labour in routine clinical situations.Prospective cohort study.28 hospitals in the Netherlands and Belgium.1920 consecutive women treated with tocolytics for threatened preterm labour.Maternal adverse events (those suspected of being causally related to treatment were (...) considered adverse drug reactions) leading to cessation of treatment.An independent panel evaluated the recorded adverse events, without knowledge of the type of tocolytic used. Of the 1920 women treated with tocolytics, 1327 received a single course of treatment (69.1%), 282 sequential courses (14.7%), and 311 combined courses (16.2%). Adverse drug reactions were categorised as serious or mild in 14 cases each. The overall incidence of serious adverse drug reaction was 0.7%. Compared with atosiban

Full Text available with Trip Pro

2009 BMJ

10. The use of tocolytic therapy in a pregnant trauma patient

The use of tocolytic therapy in a pregnant trauma patient BestBets: The use of tocolytic therapy in a pregnant trauma patient The use of tocolytic therapy in a pregnant trauma patient Report By: Helene Svinos - Medical Student Search checked by Anna O' Malley - Medical Student Institution: University of Manchester Date Submitted: 9th June 2008 Date Completed: 11th March 2009 Last Modified: 11th March 2009 Status: Green (complete) Three Part Question In a [pregnant trauma patient] does (...) [tocolytic therapy] improve [outcome for mother and foetus]? Clinical Scenario A pregnant woman of 32 weeks gestation is admitted to the ED after a fall. She has blunt abdominal trauma and is having what seem to be uterine contractions. You wonder whether you start tocolytic therapy to try to prevent or delay a premature delivery and so prevent some of the possible complications for both mother and baby. Search Strategy Medline 1950 to November week 1 2008 using Ovid Interface EMBASE 1980-2008 Week 1

2009 BestBETS

11. Tocolytic therapy: a meta-analysis and decision analysis

Tocolytic therapy: a meta-analysis and decision analysis Tocolytic therapy: a meta-analysis and decision analysis Tocolytic therapy: a meta-analysis and decision analysis Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM CRD summary The review concluded that all current tocolytic agents were superior to no treatment at delaying delivery of newborns for both 48 hours and seven days. In light of the limited assessment of study quality, questionable statistical (...) techniques used and an absence of any statistical investigation into variation between studies, the authors' conclusions are not likely to be reliable. Authors' objectives To determine the optimal first-line tocolytic agent for treatment of premature labour. Searching MEDLINE, EMBASE, CINAHL and Cochrane Database of Clinical Trials were searched (without language restrictions) for full published papers with dates that ranged from 1950 to January 2008; search terms were reported. Cochrane reviews were

Full Text available with Trip Pro

2009 DARE.

12. Review: oxytocin receptor antagonists for preterm labour do not improve infant outcomes more than placebo or other tocolytics

Review: oxytocin receptor antagonists for preterm labour do not improve infant outcomes more than placebo or other tocolytics Review: oxytocin receptor antagonists for preterm labour do not improve infant outcomes more than placebo or other tocolytics | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: oxytocin receptor antagonists for preterm labour do not improve infant outcomes more than placebo or other tocolytics Article Text

2007 Evidence-Based Medicine (Requires free registration)

13. Clinical and cost-effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations

Clinical and cost-effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations Clinical and cost-effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations Clinical and cost-effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations Lam F, Bergauer N K, Jacques D (...) , Coleman S K, Stanziano G J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two methods of treating recurrent preterm labour in twin gestations, continuous subcutaneous terbutaline (SQT) and oral tocolytics (PO), were examined. Type

2001 NHS Economic Evaluation Database.

14. Tocolytic therapy for preterm labor

Tocolytic therapy for preterm labor Tocolytic therapy for preterm labor Tocolytic therapy for preterm labor Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Tocolytic therapy for preterm labor. Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2000 Authors (...) ' objectives This review aims to assess the available evidence on the effectiveness of tocolytic therapy for preterm labor. Authors' conclusions With regard to the use of tocolytic therapy for preterm labor, the ICSI Technology Assessment Committee finds the following: The effectiveness of magnesium sulfate, nifedipine, and ritodrine may be comparable when used to delay delivery for 24 to 48 hours but with limited data from placebo-controlled trials it is impossible to conclude that any of the agents

2000 Health Technology Assessment (HTA) Database.

15. Tocolytics for preterm labor: a systematic review

Tocolytics for preterm labor: a systematic review Tocolytics for preterm labor: a systematic review Tocolytics for preterm labor: a systematic review Gyetvai K, Hannah M E, Hodnett E D, Ohlsson A Authors' objectives To examine the effectiveness of any tocolytic compared with a placebo or no tocolytic for preterm labour. Searching The authors searched the MEDLINE (1966-1998) electronic database and the Cochrane Controlled Trials Register using the search terms: 'randomized controlled trial' (RCT (...) -up exceeded 20% of those originally enrolled, or if data was not reported on a per-patient-treated basis. Specific interventions included in the review Tocolytics for the intervention group and placebo or no tocolytic for the control group. Tocolytics used in the intervention group included: isxuprine, ethanol, terbutaline, ritodrine, indomethacin, magnesium sulfate and atosiban. The dosages are not stated. Participants included in the review Women in preterm labour. Outcomes assessed

1999 DARE.

16. Evidence for magnesium sulfate as a tocolytic agent

Evidence for magnesium sulfate as a tocolytic agent Evidence for magnesium sulfate as a tocolytic agent Evidence for magnesium sulfate as a tocolytic agent Macones G A, Sehdev H M, Berlin M, Morgan M A, Berlin J A Authors' objectives To assess the efficacy and side-effects of magnesium sulfate for acute tocolysis, compared with both placebo and beta-agonists. Searching Two authors independently searched MEDLINE from 1966 to 1996 for RCTs published in the English language, using the keywords (...) and death, and whether individual tocolytes increase the risk of adverse outcomes. Bibliographic details Macones G A, Sehdev H M, Berlin M, Morgan M A, Berlin J A. Evidence for magnesium sulfate as a tocolytic agent. Obstetrical and Gynecological Survey 1997; 52(10): 652-658 PubMedID Other publications of related interest 1. Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981;2:31-49. 2

1997 DARE.